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Among t�e p�otosensitizing substances� utilized for 
p�otodynamic t�erapy of tumors �PDT�� �-aminolevu-
linic acid �ALA� is t�e only one t�at is not a p�otosen-
sitizer proper but a metabolic precursor of an active 
product protoporp�yrin IX �Pp IX� in w�ic� it converts 
upon introduction into organism [1� �]. T�erefore� levels 
of t�e Pp IX accumulation in different tissues may vary 
depending on tissue metabolism. It was s�own t�at 
in tumors t�e Pp IX formation from exogenic ALA was 
more intensive t�an in normal tissues [�� 4] presumably 
because malignant cells �ave �ig�er activity of rate-lim-
iting enzyme porp�obilinogen deaminase [�] and lower 
activity of anot�er enzyme ferroc�elatase [�] controlling 
under normal conditions t�e Pp IX overproduction by its 
transformation to �eme [7].
Taking into account t�at p�otodynamic elimination 
of malignant lymp�ocytes may potentially �ave some 
important practical applications �e. g.� graft purging 
from residual leukemic cells in t�e course of autolo-
gous bone marrow transplantation; PDT of cutaneous 
T-cell lymp�omas�� we set t�e task of studying antileu-
kemic efficiency of ALA-mediated PDT using as model 
targets bot� �uman leukemia cell lines and neoplastic 
lymp�ocytes isolated from patients wit� different 
forms of leukemia. T�e results obtained demonstrate 
pronounced difference in resistance to ALA-PDT of 
lymp�ocytes from leukemic patients compared to t�e 
cells from normal subjects suggesting t�e possibility 
to employ t�is difference as an additional marker of 
lymp�oid malignancy.
MATERIALS AND METHODS
�ononuclear cells� �ereafter referred to as lymp�o-
cytes� were isolated from fres�ly drawn �eparinized 
perip�eral blood of �� �aematologic patients� w�ic� 
were treated in different Kiev clinics� and � �ealt�y 
donors �� men and � women� median age �1 years� 
range ���4�� by a density-gradient tec�nique �Ficoll-
sodium metrizoate d = 1.�77 g/cm� � [�]. Preliminary 
clinical dia gnoses of c�ronic lymp�oproliferative 
disorders were verified by aut�ors on t�e grounds of 
morp�ological� cytoc�emical and immunocytoc�emi-
cal investigations of perip�eral blood and bone marrow 
cells [�]. Immunop�enotype determination was carried 
out by means of a panel of monoclonal antibodies 
�DakoCytomation� Denmark� to differentiation antigens 
of T lymp�ocytes �CD�� CD�� CD4� CD�� CD7� CD��� 
B lymp�ocytes �CD1�� CD��� CD��� CD4��� and NK 
cells �CD1�� CD�7�� and by immunocytoc�emical ABC-
AP met�od [�]. From eac� patient an informed consent 
to participate in t�e investigation was obtained.
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B-cell lines Raji and Namalwa ��uman Burkitt lym-
p�oma� [1�� 11] and T-cell lines �T-4 ��uman T-cell 
leukemia� [1�] and HUT-7� ��uman cutaneous T-cell 
lymp�oma� [1�] were obtained from culture bank of 
R.E. Kavetsky Institute for Experimental Pat�ology� On-
cology and Radiobiology and were cultured in standard 
RP�I-1�4� medium supplied wit� 1�% fetal bovine 
serum. For p�otodynamic treatment� cell suspen-
sions in Hanks’ balanced salt solution �pH = 7.�� were 
prepared from cultures of leukemic cell lines in log 
p�ase of growt� or lymp�ocytes fres�ly isolated from 
�eparini zed blood. Solutions of ALA �Synbias� Ukraine� 
were prepared immediately before experiments in 
t�e buffe red salt solution� pH = 7.�. A cell suspension 
�� · 1��/ml� was incubated for 4 � wit� 1.���.� m� ALA 
under �7 °C and t�en irradiated by �elium-neon laser 
�wavelengt� of ��� nm�. Irradiation doses varied from 
1� J/cm� to 1�� J/cm� depending on cell resistance. 
After t�e lig�t treatment� cells were incubated ��7 °C� 
in RP�I-1�4� medium wit� fetal serum for additional 
�� � for p�otodynamic alterations to fully develop. T�e 
number of dead cells was determined by trypan blue 
dye exclusion test.
RESULTS
Lymp�ocytes isolated from �ealt�y donors turned 
out quite resistant to t�e p�otodynamic treatment wit� 
ALA. As it is s�own in Table 1� application of t�e entire 
range of tested doses up to 1�� J/cm�� t�at was � times 
more t�an t�e dose served usually as an effective 
standard in experiments wit� malignant lymp�ocytes 
��� J/cm��� could not induce any significant deat� 
of treated cells. Equally unsuccessful were attempts 
to boost p�otodynamic alteration of t�e cells raising 
concentration of ALA from 1 m� �used for evaluation of 
lymp�ocytes killing in studies wit� leukemia patients� 
to ��� m�. 
On t�e contrary� lymp�ocytes obtained from pa-
tients wit� lymp�atic leukemia� yielded in general easily 
to p�otodynamic damage �Table ��. In � from 1� suc� 
patients �№ 1�7� 1�� 1��� more t�an ��% of cells died 
under c�osen standard regimen of PDT treatment 
�1 m� ALA� �� J/cm��. �ost �7� of t�ese � leukemia 
cases were diagnosed by cell cytomorp�olo gy and 
immunop�enotype as B-cell c�ronic lymp�ocytic 
leukemia �B-CLL�. Among ot�er 7 cases� in � patients 
wit� B-CLL �№ �� �� 1�� t�e number of dead cells 
also approac�ed ��% �4�� 4�� 41%�. And only in re-
mainder 4 patients �№ 11 — �airy cell leukemia and 
№ 14�1� — T-cell large granular lymp�ocyte leuke-
mia� t�e number of dead cells was low: �4.4; �.7; 4% 
and 1�%� respectively. 
For t�e sake of comparison� in t�e Table � t�ree cases 
�№ 1����� are also given in w�ic� a preliminary clinical 
diagnosis of leukemia was not confirmed by laboratory 
investigations� and t�e cell response to p�otodynamic 
treatment proved to be accordingly insignificant: �.7; 
�.�% and 17.�% of dead cells� respectively.
In parallels wit� lymp�ocytes isolated from blood of 
leukemia patients� resistance to ALA-PDT of leukemic 
B-cell lines �Raji and Namalwa� and T-cell lines ��T-4 
and HUT-7�� was studied . P�otodynamic vulnerability 
of t�ese cultured neoplastic lymp�ocytes was also 
found to be by far exceeding suc� of normal blood 
lymp�ocytes �see Table ��. And as it is seen from t�e 
Table �� among 4 cultures tested� Raji stood out for 
its comparatively �ig� resistance to ALA-PDT w�ile 
HUT-7� seemed to be t�e most responsive.
Table 1. ALA-PDT action on lymphocytes of healthy donors
Donors ALA concentra-tion (mM)
Laser radiation 
doses (J/cm2)
Number of dead 
cells (%)
№ 1 1.0 10.0 1.0
1.0 18.0 1.0
1.0 25.0 1.0
№ 2 2.0 10.0 0.0
2.0 18.0 0.2
2.0 25.0 0.5
№ 3 3.0 10.0 1.0
3.0 18.0 1.0
3.0 25.0 1.0
№ 4 4.0 10.0 0.0
4.0 18.0 0.0
4.0 25.0 0.1
№ 5 2.0 50.0 0.5
№ 6 5.0 100.0 1.5
5.0 150.0 1.5
Control (untreated cells) 0.5
DISCUSSION
In addition to selective low-invasive destruction 
of tumors� PDT may be instrumental in elimina-
tion of malignant lymp�oid cells� as it is illustrated 
by bone marrow transplants purging from residual 
leukemic cells wit� merocyanine �4� assisted PDT 
[14]� a procedure proposed to improve efficiency of 
leukemia patients’ t�erapy. In t�at case� selectivity of 
malignant lymp�ocytes killing� as opposed to normal 
lymp�ocytes and bone marrow progenitors� acquires 
particular importance.
T�e data presented �ere s�ow t�at t�ere is a striking 
difference in responsiveness to ALA mediated PDT of 
blood lymp�ocytes obtained from �ealt�y subjects and 
leukemia patients. W�ereas in most cases� a bulk of 
leukemic cells were quite easily destroyed by ALA-PDT 
wit�out necessity to resort to �ig�er p�otosensitizer 
concentrations or lig�t radiation doses �see Table �� 
№ 1�1�� 1�� 1��� it was virtually impossible to attain any 
appreciable damage of normal lymp�ocytes even wit� 
t�e largest ALA-PDT doses tested. T�e contrasting re-
actions observed may be explained by peculiarities of 
�eme metabolism in malignant cells. Heme synt�esis 
from glycine and succinyl CoA under normal conditions 
is a subject of t�e negative feedback regulation [7]: 
an increase in t�e �eme formation in�ibits activity of 
a rate limiting enzyme aminolevulinat- synt�ase and 
decreases ALA concentration. If exogenic ALA is in-
troduced in organism t�e limiting link is passed round� 
and t�e process proceeds down t�e c�ain to synt�esis 
of Pp IX. In normal lymp�ocytes� t�e Pp IX by means of 
ferroc�elatase joins Fe�+ being transformed to �eme 
t�at unlike PpIX �as no p�otosensitizing properties. 
But in malignant cells� ferroc�elatase activity is low 
[�]. W�at is more� in t�e cells� intracellular iron stores 
are spent for DNA and cytoc�rome synt�esis [1�]. As 
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a result� in malignant cells Pp IX is accumulated giving 
rise to t�e cell p�otosensitivity.
It is of note t�at most of t�e cases analyzed �ere� 
t�at s�owed considerable lymp�ocyte responsive-
ness to ALA-PDT� were constituted by B-cell leukemia 
patients� including 1� patients wit� B-CLL. Ot�er four 
cases were a patient wit� T-cell c�ronic lymp�atic leu-
kemia �see Table �� № 1�� and t�ree patients wit� Т-cell 
large granular lymp�ocyte leukemia �see Table �� 
№ 14�1��. Curiously enoug�� t�ese four cases occu-
pied extreme �but opposite� positions on t�e general 
�for studied leukemia patients� scale of ALA-PDT lym-
p�ocyte responsiveness: t�e first one wit� t�e largest 
portion of cells killed ���%� and t�e ot�er t�ree — wit� 
t�e smallest ��.7; 4; 1�%�. It remains to wait until more 
patients wit� t�ese leukemia types are analysed to de-
cide w�et�er suc� reactivity levels are typical of t�em. 
As to B-CLL patients� it seems t�at more t�an 4�% kill-
ing of lymp�ocytes �mean for 1� patients is �����% ± 
4���%� under standard conditions c�osen is quite 
c�aracteristic. Given relatively �ig� incidence of B-CLL 
among t�e elderly population [1�]� drastic distinctions 
in lymp�ocytes ALA-PDT responsiveness between t�e 
patients and �ealt�y people s�ould be evaluated as 
a possible simple and low-traumatic test for B-CLL 
screening� especially if it is establis�ed t�at t�ere is 
no essential overlap in t�e cell reactivity wit� reactive 
lymp�ocytosis �t�e work in progress�. In t�is connec-
tion� t�ree cases wit� negative diagnoses� deliberately 
included in Table � �№ 1������ are demonstrative. As 
it �appened� ALA-PDT responsiveness tests wit� t�e 
patients were carried out before immunocytological 
investigation of t�e material �responsibility of anot�er 
laboratory� was accomplis�ed� and strong doubts were 
cast on t�e preliminary leukemia diagnosis forestalling 
a formal diagnostic conclusion.
It was interesting to find out w�et�er leukemic lym-
p�ocytes� cultured as establis�ed cell lines� retain t�eir 
�ig�tened ALA-PDT responsiveness in comparison to 
normal cells. T�e data obtained wit� two B-cell lines 
�Namalwa and Raji� and two T-cell lines ��T-4 and 
HUT-7�� witness t�at it is t�e case �Table �� and cor-
roborate t�e findings of ot�er aut�ors [17���]� t�oug� 
all of t�em worked wit� some ot�er leukemic cell lines. 
From Table � it also appears t�at among four cell lines 
studied� t�e Raji is distinctly distinguis�ed by its rela-
tively low responsiveness� surprisingly independent of 
ALA-PDT doses applied. Considering t�e leading role 
apoptotic mec�anisms play in p�otodynamic damage 
of tumors [�4]�t�e anomalous reaction of Raji cells is 
presumably connected wit� altered apoptosis pat�-
ways discovered in t�e cells [��]. Taken as a w�ole� 
two T-cell lines tested are more ALA-PDT responsive 
t�an B cell lines �could t�at be correlated to extremely 
�ig� cell responsiveness of t�e only T-cell leukemia 
patient analysed �see Table �� № 1��?�. 
To t�e best of our knowledge� t�ere are no publis�ed 
data on t�e ALA-PDT responsiveness of lymp�ocytes 
from patients wit� lymp�atic leukemia. In a paper [��]� 
preferential ALA-PDT killing of malignant lymp�ocytes 
from a patient wit� cutaneous T-cell lymp�oma com-
pared to normal perip�eral blood lymp�ocytes was 
described. Hrkal`s group reported [�7] t�at in � out 
of 1� patients wit� acute myeloid leukemia� ALA-PDT 
treatment of mononuclear cell preparations resulted in 
substantial reduction of blast cells number w�ereas t�e 
viability of normal lymp�ocytes was little affected.
Table 3. ALA-PDT action on leukemia cell lines
Cell lines ALA concentra-tion (mM)
Laser radiation 
doses (J/cm2)
Number of dead 
cells (%)
B-cell lines
Raji 1.0 25 18.25 ± 1.7
2.5 50 15.3 ± 2.3
4.0 100 17.0 ± 2.0
Namalwa 1.0 25 36.0 ± 5.7
2.5 50 63.5 ± 2.5
3.0 75 97.6 ± 3.1
T-cell lines
MT-4 1.0 25 54.8 ± 3.4
2.5 50 96.3 ± 4.8
HUT-78 1.0 10 74.3 ± 2.3
1.0 25 95.7 ± 0.8
Table 2. ALA-PDT action on lymphocytes of patients with hematological diseases
Pa-
tients Diagnoses
 Phenotype (positive cells, %) Number of 
dead cells (%)CD19 CD20 CD23 CD43 CD2 CD3 CD4 CD5 CD7 CD8 CD16 CD57
1 B-cell chronic lymphatic leukemia (B-CLL) 80 85 65 7 7 55 7 7 73.5 ± 2.36
2 B-CLL 90 90 90 5 Single 
cells
95 Single 
cells
Single 
cells
61.8 ± 5.48
3 B-CLL 80 80 70 12 7 90 7 7 53.0 ± 2.1
4 B-CLL/non-Hodgkin`s lymphoma 50 50 54 80 37 82 60.3 ± 7.74
5 B-CLL 90 90 80 5 Single 
cells
90 Single 
cells
Single 
cells
85.4 ± 4.09
6 B-CLL 75 70 60 80 15 67.2 ± 4.42
7 B-CLL 85 75 65 20 50 72.8 ± 4.66
8 B-CLL 70 64 50 24 57 48.0 ± 2.03
9 B-CLL 70 75 26 24 13 52 12 12 45.0 ± 2.16
10 Non-Hodgkin`s lymphoma (early leuke-
mization phase)
65 70 30 18
15 15 53.6 ± 2.4
11 Hairy cell leukemia 50 53 -/+ 43 43 42 43 43 24.4 ± 2.68
12 B-CLL 55 60 50 37 20 55 18 17 41.0 ± 2.7
13 T-cell chronic lymphatic leukemia 95 90 88 80 0 90.0 ± 3.5
14 Large granular lymphocytic leukemia, 
T-cell variant (T-LGLL)
99 90 90 68 36 3.7 ± 1.03
15 T-LGLL 85 90 90 90 25 10 8 4.0 ± 0.5
16 T-LGLL 93 95 10 25 77 63 79 16.0 ± 1.76
17 Langerhan`s cell histiocytosis 11 11 73 30
30 34
20.5 ± 1.84
18 Polyclonal B-lymphocyte proliferation 33 28 60 5.7 ± 1.2
19 Polyclonal B-lymphocyte proliferation 21 17 84 78 6.6 ± 0.24
20 Polyclonal B-lymphocyte proliferation 17.2 ± 1.96
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ЧУВСТВИТЕЛЬНОСТЬ НОРМАЛЬНЫХ 
И МАЛИГНИЗИРОВАННЫХ ЛИМФОЦИТОВ ЧЕЛОВЕКА 
К ФОТОДИНАМИЧЕСКОМУ ВОЗДЕЙСТВИЮ, 
ОПОСРЕДОВАННОМУ 5-АМИНОЛЕВУЛИНОВОЙ КИСЛОТОЙ
Цель: изучить чувствительность к фотодинамическому воздействию, опосредованному 5-аминолевулиновой кислотой (АЛК), 
нормальных и малигнизированных лимфоцитов человека. Методы: объектом исследования служили лимфоциты, выделенные 
с помощью градиента плотности фиколл-верографина из крови здоровых доноров (6) и гематологических больных (20) 
с различными формами лимфолейкозов, а также трансформированные лимфоциты В-клеточных (Raji, Namalwa) и Т-клеточных 
(МТ-4, HUT-78) линий человека. Диагноз хронического лимфопролиферативного заболевания ставили на основании 
морфологического, цитохимического и иммуноцитохимического исследования периферической крови и клеток костного мозга; 
иммунофенотипирование проводили с использованием панели моноклональных антител к дифференцировочным антигенам 
Т-, В-лимфоцитов, NK-клеток и АВС-АР-метода. Трансформированные лимфоциты клеточных линий культивировали в 
стандартной RPMI-1640 среде с 10% эмбриональной телячьей сывороткой. Для фотодинамического воздействия клетки 
инкубировали с 1,0–5,0 мМ АЛК в течение 4 ч и облучали гелий-неоновым лазером (длина волны – 633 нм), варьируя дозу от 
10 до 150 Дж/см2 . Количество погибших клеток после дополнительной 20-часовой инкубации определяли с помощью теста 
с трипановым синим. Результаты: показано, что нормальные и малигнизированные лимфоциты человека резко отличаются по 
чувствительности к АЛК-опосредованному фотодинамическому действию (АЛК-ФД). Значительная часть лимфоцитов крови 
больных лейкозом (в среднем 62,06 ± 4,03% у 10 пациентов с В-клеточным хроническим лимфолейкозом, В-ХЛЛ) погибала 
при минимальных параметрах воздействия (1 мМ АЛК, доза облучения 25 Дж/см2 ), тогда как даже наивысшая доза (5 мМ 
АЛК, 150 Дж/см2) не влияла на жизнеспособность нормальных лимфоцитов. В опытах in vitro в Т-клеточных линиях отмечали 
больший процент гибели клеток, чем в В-клеточных. При этом линия Raji отличается парадоксальным отсутствием зависимости 
количества погибших клеток от дозы воздействия, что, по-видимому, связано с известным для этой линии дефектом сигнальных 
путей апоптоза. Обсуждаются вероятные механизмы установленных отличий между нормальными и малигнизированными 
лимфоцитами в контексте альтерации процессов синтеза клетками гема при малигнизации. Выводы: 1) впервые показано, 
что малигнизированные лимфоциты крови больных лимфолейкозом проявляют высокую чувствительность к АЛК-ФД 
при фактическом отсутствии такой чувствительности у лимфоцитов здоровых доноров; 2) озлокачествленные лимфоциты 
Т-клеточных линий более чувствительны к АЛК-ФД по сравнению с В-клеточными; 3) для клеток линии Raji установлена 
аномальная зависимость доза/эффект; 4) на основе полученных результатов предложен простой и малотравматичный тест 
для скрининга пожилых людей на наличие В-ХЛЛ. 
Ключевые слова: лимфоциты крови, здоровые доноры, больные лейкозом, клеточные линии, фотодинамическое воздействие, 
5-аминолевулиновая кислота, скрининг В-ХЛЛ.
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